AXIM Biotechnologies Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	3.2yrs
Gemiddelde ambtstermijn bestuur	3.1yrs

Recente managementupdates

Recent updates

CEO

AXIM Biotechnologies heeft geen CEO, of we hebben geen gegevens over hen.

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Catalina Valencia	President & Director	less than a year	US$187.50k	8.03% $ 95.4k
Robert Malasek	CFO & Secretary	8.4yrs	US$90.00k	0.016% $ 190.0
Kurt Phinney	Chief Operating Officer	1.5yrs	geen gegevens	geen gegevens
Sergei Svarovsky	Chief Scientific Officer & Co-Founder of Sapphire Biotech	no data	geen gegevens	6.33% $ 75.2k
Douglas Lake	Chief Clinical Officer of Sapphire Biotech	no data	US$164.43k	geen gegevens
Alim Seit-Nebi	CTO & Co-Founder of Sapphire Biotech	no data	US$82.22k	geen gegevens
Jeffrey Busby	Senior Vice President of Business Development	3.2yrs	geen gegevens	geen gegevens
Joseph Tauber	Chief Medical Officer & Chairman of the Medical Advisory Board	3.2yrs	geen gegevens	geen gegevens
Maria J. Moa	Vice President of Product Development - Sapphire Biotech	no data	geen gegevens	geen gegevens

3.2yrs

Gemiddelde duur

61.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van AXIM wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Catalina Valencia	President & Director	less than a year	US$187.50k	8.03% $ 95.4k
Joseph Tauber	Chief Medical Officer & Chairman of the Medical Advisory Board	3.2yrs	geen gegevens	geen gegevens
Timothy Scott	Independent Director	7.5yrs	US$20.00k	0.11% $ 1.3k
Kelly Nichols	Member of Medical Advisory Board	3.1yrs	geen gegevens	geen gegevens
Robert Cunningham	Independent Director	7.5yrs	US$20.00k	0.11% $ 1.3k
Blake Schroeder	Director	2.8yrs	US$20.00k	0% $ 0
Michael Stern	Member of Medical Advisory Board	3yrs	geen gegevens	geen gegevens
Henry Perry	Member of Medical Advisory Board	3.1yrs	geen gegevens	geen gegevens
Peter O'Rourke	Director	4.3yrs	US$20.00k	0.080% $ 950.0
Laura Periman	Member of Medical Advisory Board	3.1yrs	geen gegevens	geen gegevens

3.1yrs

Gemiddelde duur

71yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van AXIM wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.1 jaar).

AXIM Biotechnologies Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

AXIM Biotechnologies, Inc. Announces Management Changes

AXIM Biotechnologies, Inc. Appoints Kurt Phinney as Chief Operating Officer

Recent updates

AXIM Biotechnologies, Inc. Announces Management Changes

AXIM Biotechnologies, Inc. announced delayed 10-Q filing

AXIM Biotechnologies, Inc. announced delayed 10-Q filing

AXIM Biotechnologies, Inc. announced delayed annual 10-K filing

AXIM Biotechnologies, Inc. announced delayed 10-Q filing

AXIM Biotechnologies Develops First Non-Invasive, Rapid, Point-Of-Care, Diagnostic Test for Parkinson's Disease

AXIM Biotechnologies, Inc. Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test

AXIM Biotechnologies, Inc. Appoints Kurt Phinney as Chief Operating Officer

AXIM Biotechnologies, Inc. announced delayed 10-Q filing

AXIM Biotechnologies, Inc. Files Patent on Fentanyl Neutralizing Antibody Test, Applies for Drug Enforcement Administration License to Work with Controlled Substance

AXIM Biotechnologies, Inc. Develops Novel Dual IgE/MMP-9 Rapid Ophthalmological Diagnostic Test and Files Provisional Patent

AXIM Biotechnologies, Inc. announced that it has received $0.1 million in funding

AXIM Biotechnologies, Inc. announced delayed 10-Q filing

AXIM Biotechnologies, Inc. Enhances IgE Testing Capabilities; Responds to Global Warming's Impact on Allergy Season

AXIM Biotechnologies Publishes Study Highlighting Neutralizing Antibody Levels of Poor Vaccine Responders with A Third Covid-19 Vaccine Dose

AXIM Biotechnologies, Inc Completes Optimization of Only FDA-Cleared IgE Rapid Diagnostics Test – In-House Manufacturing Lowers Cost and Eliminates Supply Chain Expenditures

AXIM Biotechnologies, Inc Completes Optimization of Only FDA-Cleared IgE Rapid Diagnostics Test – In-House Manufacturing Lowers Cost and Eliminates Supply Chain Expenditures

AXIM Biotechnologies, Inc. announced delayed 10-Q filing

AXIM Biotechnologies, Inc. Develops Novel Tear Sample Collector System, Files Patent Application

AXIM Biotechnologies, Inc. Develops Quantitative Rapid Diagnostic Test for Lacritin, Now Boasts Four Dry Eye Disease Point-Of-Care Biomarker Tests

AXIM Biotechnologies, Inc. announced delayed annual 10-K filing

AXIM Biotech Develops Rapid Quantitative Tear Test for MMP-9

Centers for Disease Control and Prevention Publishes Axim Biotechnologies-Sponsored Study on Covid-19 Neutralizing Antibodies

AXIM Biotechnologies, Inc. announced delayed 10-Q filing

AXIM Biotechnologies, Inc. Completes Pre-Clinical Drug Studies on SPX-1009 Compound Proving Suppression of Melanoma Cells

AXIM Biotechnologies, Inc. announced delayed 10-Q filing

AXIM® Biotechnologies’ Manufacturing Partner Empowered Diagnostics Files for Approval for Use of Rapid Covid-19 Neutralizing Antibody Test in Whole Blood At Point-Of-Care Locations in Canada and the EU

AXIM Biotechnologies, Inc. Introduces Diagnostics to Measure Immunity Against Emerging SARS-CoV-2 Variants

AXIM Biotechnologies, Inc. announced delayed annual 10-K filing

AXIM Biotechnologies Successfully Completes Point-of-Care Clinical Trials on its Rapid COVID-19 Neutralizing Antibody Test

AXIM Biotechnologies Begins Clinical Trials on Its ImmunoPass Rapid Diagnostic Test With Vaccine Recipients

AXIM Biotechnologies Releases Preprint Manuscript Describing the Development of Company’S Rapid Point-Of-Care Test That Measures Covid-19 Neutralizing Antibodies

AXIM Biotechnologies, Inc. Completes Successful Covid-19 Live Virus Test and Files Amended EUA for Portable 10 Minute Rapid Diagnostic Test for Neutralizing Antibodies

AXIM Biotechnologies Develops ELISA-Based Neutralizing Antibody Diagnostic Test for COVID-19

AXIM Biotechnologies, Inc. announced delayed 10-Q filing

Axim Biotechnologies Files Patent for Face Mask Designed to Capture SARS-CoV-2 COVID-19

AXIM Biotechnologies Files Emergency Use Authorization with the FDA for First–In-Class Covid-19 Rapid Diagnostic Test for Neutralizing Antibodies

CEO

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd